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ATM (ataxia-telangiectasia, mutated) is an important cancer susceptibility gene that encodes a key apical kinase
in the DNA damage response pathway. ATM mutations in the germ line result in ataxia-telangiectasia (A-T), a
rare genetic syndrome associated with hypersensitivity to double-strand DNA breaks and predisposition to
lymphoid malignancies. ATM expression is limited by a tightly regulated nonsense-mediated RNA decay
(NMD) switch exon (termed NSE) located in intron 28. In this study, we identify antisense oligonucleotides that
modulate NSE inclusion in mature transcripts by systematically targeting the entire 3.1-kb-long intron. Their
identification was assisted by a segmental deletion analysis of transposed elements, revealing NSE repression
upon removal of a distant antisense Alu and NSE activation upon elimination of a long terminal repeat trans-
poson MER51A. Efficient NSE repression was achieved by delivering optimized splice-switching oligonucle-
otides to embryonic and lymphoblastoid cells using chitosan-based nanoparticles. Together, these results provide
a basis for possible sequence-specific radiosensitization of cancer cells, highlight the power of intronic antisense
oligonucleotides to modify gene expression, and demonstrate transposon-mediated regulation of NSEs.
Keywords: alternative splicing, transposon, nonsense-mediated RNA decay, antisense oligonucleotides, ATM,
lymphoid cancer, nanoparticles
Introduction
Eukaryotic genes contain intervening sequences orintrons that must be removed by a large and highly
dynamic RNA protein complex termed the spliceosome to
ensure accurate protein synthesis [1]. The cell requires ex-
cessive energy and time to complete transcription of intron-
containing precursor messenger RNAs (pre-mRNAs) from at
least a quarter of the human genome and also needs to syn-
thesize noncoding RNAs and >200 different spliceosomal
proteins to achieve this task [1]. Although once regarded a
selfish or junk DNA, introns are now recognized as critical
functional components of eukaryotic genes that enhance gene
expression and regulate alternative RNA processing, mRNA
export, and RNA surveillance [2,3]. They are also an im-
portant source of new gene-coding and regulatory sequences
[1,4,5] and noncoding RNAs, including microRNAs and
circular RNAs [6,7]. Their removal process is tightly cou-
pled with transcription, mRNA export, and translation, with
most human introns eliminated from pre-mRNA cotran-
scriptionally [8]. However, their potential as targets for nu-
cleic acid therapy is only beginning to be unleashed.
Spliceosomes assemble ad hoc on each intron in an or-
dered manner, starting with recognition of the 5¢ splice site
(5¢ss) by the U1 small nuclear ribonucleoprotein or the 3¢ss
by the U2 pathway [1,9]. In addition to traditional splice site
recognition sequences (5¢ss, branch point, polypyrimidine
tract, and 3¢ss), accurate splicing requires auxiliary sequences
or structures that activate or repress splice sites, known as
intronic or exonic splicing enhancers or silencers. These el-
ements allow genuine splice sites to be recognized among a
vast excess of cryptic or pseudosites in vertebrate genomes
that have similar sequences, but outnumber authentic sites by
an order of magnitude [10]. Activation of cryptic splice sites
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can introduce premature termination codons (PTCs) in
translational reading frames and may lead to genetic disease
[11]. Such transcripts are usually recognized by a nonsense-
mediated RNA decay (NMD) pathway and downregulated
[12]; however, cryptic exons and NMD play also an important
role in controlling the expression of naturally occurring tran-
scripts [13] and differentiation stage-specific splicing switches,
as exemplified by terminal stages of hematopoiesis [14,15]. In
addition, cryptic splice sitesmay permit unproductive or partial
spliceosome assemblies that may compete with natural splice
sites, which may facilitate their accurate selection at a single-
nucleotide resolution [16,17]. Cryptic splice sites can activate
pseudoexons that limit gene expression (also known as poison
or NMD switch exons), thus regulating the pool of mRNA
isoforms and providing interesting targets for nucleic acid
therapeutics [18]. However, potential exploitation of such
strategies is in its infancy.
Splice-switching oligonucleotides (SSOs) are antisense re-
agents that modulate intron splicing by binding splice site
recognition or regulatory sequences and competing with cis-
elements or trans-acting factors for their targets [19–21]. They
have been shown to restore aberrant RNA processing, modify
the relative abundance of existing mRNA isoforms, or produce
novel splice variants that are not normally expressed by the cell
[20]. Most SSOs employed in preclinical and clinical devel-
opment have targeted exonic sequences [19–21]. Whereas
most exonic SSOs designed to induce exon skipping usually
have a desired effect, functional intronic SSOs are more dif-
ficult to identify, unless they block access to intronic cryptic
splice sites activated by a disease-causing mutation. First, a
large fraction of intronic sequences may not affect RNA pro-
cessing at all, despite the wealth of intronic auxiliary splicing
motifs in the human genome [22]. In addition, a search for
functional intronic SSOs that produce desirable RNA proces-
sing outcomes is usually inefficient and costly and may fail
completely. For example, most SSOs systematically covering
exon 7 of the SMN2 (survival of motor neuron 2) gene stim-
ulated exon skipping, a prerequisite for antisense therapy of
spinal muscular atrophy; however, *20% SSOs increased
exon inclusion [23]. By contrast, stimulation of intron splicing
was found only for *10% of SSOs targeting INS intron 1,
while themajority failed to show this effect [24]. Third, introns
are enriched for many repetitive elements that preclude the
SSO use with endogenous targets. Identification of effective
intronic SSOs may be facilitated by global pre-mRNA folding
and ultraviolet cross-linking and immunoprecipitation studies
that identify binding sites for components of the spliceosome
[18,25] or the exon junction complex [26]. However, these
binding sites may not reflect optimal antisense targets and their
resolution may be insufficient. Thus, identification of func-
tional intronic SSOs remains challenging.
Our RNA-Seq studies have recently revealed activation of
an NMD switch exon (termed NSE) deep in ATM (ataxia-
telangiectasia, mutated) intron 28 in cells depleted of each
subunit of the auxiliary factor of U2 small nuclear RNP
(U2AF) [18]. U2AF binds to polypyrimidine tracts coupled
with highly conserved 3¢ss AG dinucleotides at intron ends
and this binding promotes U2 recruitment to the branch site
and formation of lariat introns [27–29]. However, recent
identification of a large number of exons that were activated
in cells depleted of each U2AF subunit (U2AF35 and
U2AF65) and exhibited a distinct 3¢ss organization [30,31]
suggested that a subset of both canonical and NSEs is re-
pressed by U2AF, similar to exon-repressing and -activating
activities found for a growing number of RNA-binding pro-
teins [32,33]. The NSE levels were responsive to knockdown
of additional splicing factors involved in 3¢ss recognition and
were influenced by two natural DNA variants, rs609261 and
rs4988000, located in the NSE 3¢ss and further downstream,
respectively [18]. We have also identified SSOs that modu-
late NSE inclusion levels in the ATM mRNA by targeting
NSE and its competing pseudoexon in the same intron [18].
The ATM NSE provides an interesting and promising target
for anticancer therapy for several reasons: (1) the ATM ki-
nase is activated in response to double-strand breaks, mobi-
lizing an extensive signaling network with a broad range of
targets and influencing cellular sensitivity to DNA-damaging
agents [34]; (2) the U2AF-regulated exon usage in the ATM
signaling pathway is centered on the MRN/ATM-CHEK2-
CDC25 axis and preferentially involves transcripts impli-
cated in cancer-associated gene fusions and chromosomal
translocations [18]; and (3) ATM NSE activation limits ex-
pression of ATM protein in cells lacking each U2AF subunit
[18]. However, optimal NSE SSOs have not been defined and
their delivery to lymphoid cells has not been tested.
In the present study, we have systematically screened SSOs
covering unique sequences in the entire intron 28 and identify
additional SSOs that activate or repress NSE in vitro. In the
same intron, we also identify transposed elements that in-
fluence NSE inclusion inmature transcripts. Finally, we show
efficient NSE repression upon SSO delivery to embryonic and
lymphoblastoid cell lines using chitosan-based nanoparticles.
Materials and Methods
Plasmid constructs
Splicing reporter constructs containing full ATM intron 28
and flanking exons were obtained by ligating a *3.5 kb
Table 1. Cloning, RT-PCR, and Mutagenic Primers
Primer 5¢-3¢ Sequence
Cloning primers
ATM26 ataaagcttcttgttataaggttttgattcc
ATM27 atatctagatgtacataccctgaaaagtcac
RT-PCR primers
PL4 agtcgaggctgatcagcgg
ATM-F gagggtaccagagacagtgggatggc
ATM-R ggctcatgtaacgtcatcaat
Mutagenic primers
del-1F atacaatttaccataatttacttttgaattatgtt
del-1R aagtaaattatggtaaattgtatcatacattag
del-2F ccttgccagaccagtttcctagttatctatattgaac
del-2R taactaggaaactggtctggcaaggtggctta
del-3F cttcaagggaccttggccgggtgcggtggct
del-3R gcacccggccaaggtcccttgaagtttatctaa
del-4F acacaaacaaagcttaggtttctttcttgtcaccttcta
del-4R agaaagaaacctaagctttgtttgtgtgttttatacaa
del-5F tgcctcatttacgtcatacaacttaatgatagacct
del-5R ttaagttgtatgacgtaaatgaggcagggcaa
del-6F tgatacaatttacctcatacaacttaatgatagacct
del-6R attaagttgtatgaggtaaattgtatcatacattag
RT-PCR, reverse transcription polymerase chain reaction;
restriction sites are underlined.
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polymerase chain reaction (PCR) amplicon into the HindIII/
XbaI site of pCR3.1 (Invitrogen). PCR was carried out with
amplification primers, ATM26 and ATM27 (Table 1), and
DNA from human embryonic kidney HEK293 cells as a
template. PCR employed the Phusion High-Fidelity DNA
Polymerase (Thermo Scientific) at the annealing temperature
of 56C and 1.5mM MgCl2 for 30 cycles. Plasmids were
propagated in Escherichia coli (strain DH5a). Plasmid DNA
was extracted with the Gene JET Plasmid Miniprep kit
(Thermo Scientific) and separated on 1.5% agarose gels to
confirm the correct insert size following restriction enzyme
digests prior to sequence validation. Deletion constructs
(Fig. 1) were obtained by overlap extension PCR with mu-
tagenic primers (Table 1) using the validated reporter plas-
mid with the full intron as a template. Each deletion insert
was also fully sequenced to confirm the identity of intended
changes and exclude undesired mutations. Hybrid ATM
minigenes prepared by cloning *0.9-kb amplicons con-
taining NSE and exon 29 into XhoI/XbaI sites of the U2AF1
construct were described previously [18].
Splice-switching oligonucleotides
To test the effect of SSOs on both the endogenous and the
exogenous ATM pre-mRNA, SSOs were designed to avoid
transposed elements in intron 28. These elements were
identified in the human reference sequence (hg19) with the
crossmatch and slow options of the RepeatMasker web server
(v.4.0.2; www.repeatmasker.org) [35] and confirmed in our
constructs using the same method. The SSOs comprehen-
sively covered three unique regions in ATM intron 28 (termed
A, B, and AN, Fig. 2), avoiding only homopolymeric tracts.
SSOs (Eurofins) were 2¢-O-methyl modified at each ribose
and by phosphorothioates at each end linkage to ensure ad-
equate stability for the ex vivo screening. The GC content of
SSOs was at least 24% (mean 31%) and their average length
was*20 nt. SSOs were diluted in double-distilled water and
quantified using Nanodrop (Thermo Scientific). Their nor-
malized aliquots were stored at -80C.
Cell cultures and transfections of minigene constructs
HEK293 cells were maintained in standard culture con-
ditions in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% (v/v) of bovine calf serum. Cells
were seeded at 50% confluency 24 h before transfections.
Transfections of wild-type and deletion constructs were
carried out in 12- or 24-well plates using jetPRIME (Poly-
plus) according to the manufacturer’s recommendations, as
described [30]. Briefly, 250 ng of plasmid DNA was mixed
with 1.3 mL of jetPRIME in 75 mL of the jetPRIME buffer and
incubated at room temperature for 15min before adding into
cell cultures. Each SSO was transfected with and without the
full-length ATM construct using the same transfection re-
agent (2.5 mL) to a final concentration of 50 nM in each well.
The cells were harvested 24 h later for total RNA extraction
with TRI-Reagent (Ambion). Replicate experiments were
carried out 1 week later.
Determination of PU values
The PU (probability of unpaired) values estimate RNA
single-strandedness using the equilibrium partition function by
considering all possible RNA structures of short sequences,
permitting their comparison at each nucleotide position [36].
Higher PU values indicate a higher single-strandedness of
an RNA motif [36]. The PU values were computed as de-
scribed [36] using the three unique intronic regions and
their 30-bp flanks as an input. PU values for each position of
an SSO target were averaged and the means were correlated
with SSO-induced NSE inclusion levels.
Preparation of stearylated trimethyl chitosan
Trimethyl chitosan, originally derived from ultrapure
chitosan obtained from Agaricus bisporus, was provided
by KitoZyme. Purified products had the number average
FIG. 1. Identification of transposed elements in ATM in-
tron 28 that influence NSE activation. (A) Location of
transposed elements in intron 28 and schematics of NSE
activation. Canonical exons [54] are shown as gray boxes,
the NSE as a white box, introns flanking the NSE as hori-
zontal lines, and their splicing by dotted lines. Deletions
(numbered 1–6) of transposed elements are shown as hori-
zontal white rectangles; UC, a unique sequence lacking
recognizable transposons. Deletion numbers correspond to
lanes in (B). RT-PCR primers are denoted by black arrows.
A scale is at the top. The NSE sequence is boxed in the
lower panel. Asterisk denotes the C/T variant rs609261 lo-
cated at the NSE 3¢ss; rs4988000 (not shown) is 64 bp
downstream of the NSE 5¢ss. (B) Deletion of antisense Alu
and MER51 alters NSE inclusion levels. WT and mutated
constructs [designated 1–6 in (A)] were transiently trans-
fected into HEK293 cells (mock) depleted of U2AF35.
NSE+/-, RNA products with/without NSE. Columns rep-
resent mean NSE inclusion (%), error bars are SDs of two
independent transfection experiments. Asterisks denote P
values <0.01 for comparisons with the WT. 5¢ss, 5¢ splice
site; ATM, ataxia-telangiectasia, mutated; NSE, NMD
switch exon; RT-PCR, reverse transcription polymerase
chain reaction; SDs, standard deviations; WT, wild-type.
394 KRALOVICOVA ET AL.
molecular weight (Mn) of 43.3– 5.5 kDa and the polydis-
persity index (Mw/Mn) of 2.4 – 0.3, as determined by gel
permeation chromatography in a 0.33M NaCH3COOH/
0.28M CH3COOH eluent at a flow rate of 1mL/min. The
degrees of acetylation and quaternization, as determined by
the Fourier-transform infrared spectroscopy and 1H-nuclear
magnetic resonance spectroscopy (1H NMR) [37], respec-
tively, were 11.1%– 0.9% and 30.1%– 4.6%. Trimethyl
chitosan was functionalized with N-succinimidyl stearate
(Santa Cruz Biotechnologies), as previously described [37],
achieving a final degree of substitution of 2.1% – 0.6% (mol
%), as determined by 1H NMR.
Formation and delivery of nanocomplexes
The nanocomplexes were prepared by mixing equal vol-
umes (30mL) of SSO and polymer solutions, as described
previously [37]. Briefly, SSOs were diluted in buffer A
[20mM HEPES, pH 7.3, 5% (w/v) glucose] and supple-
mented with 1M Na2SO4 to a final concentration of 50mM.
Both the polymer and SSO solutions were heated at 60C for
5min before mixing with vortex at 1,000 rpm for 15 s. The
tested complexes were prepared with molar ratios of qua-
ternized amines (N) to phosphate groups (P) of 20, 40, and 80
(N/P ratios), as previously optimized for the first SSOs [37].
Their hydrodynamic diameter was between 110 and 130 nm
for the N/P ratios between 20 and 80. The complexes were
allowed to stabilize at room temperature for 30min before
adding to 240 mL DMEM without serum and antibiotics. A
final concentration of SSOs in chitosan-containing cultures
was 300 nM. Twenty-four hours after addition of complexes,
300 mL of the culture medium with serum/antibiotics was
added to HEK293 or VAVY cells. The cells were harvested
24 h later for total RNA extraction. Replicate experiments
were carried out 1 week later.
Analysis of spliced products and NSE measurements
Total RNA samples from chitosan experiments were ex-
tracted with the RNeasy kit (Qiagen). RNA was quantified
using Nanodrop (Thermo Scientific) and 1mg of total RNA
was reverse transcribed with the Moloney murine leukemia
virus reverse transcriptase (Promega) and oligo-d(T) primers.
Exogenous complementary DNA (cDNA) samples were
amplified using primers, PL4 and ATM-F, and endogenous
products were amplified with primers, ATM-F and ATM-R
(Table 1), and GoTaq polymerase (Promega) for 28 cycles
(the annealing temperature was 56C at 1.5mM MgCl2).
Spliced products were separated on 1.5% agarose and then on
6% polyacrylamide gels. The signal intensities were mea-
sured in polyacrylamide gels using FluorQuant and Phoretix
software packages (Nonlinear Dynamics, Inc.) to obtain the
percentage of NSE inclusion in polyadenylated RNAs.
Branch site prediction
The NSE branch point was predicted using the SVM-BP
finder (available at http://regulatorygenomics.upf.edu/
Software/SVM_BP/). The SVM score of the indicated NSE
branch site was 1.3.
Statistical analysis
Descriptive statistics were computed with Stat200 (Bio-
Soft). Mean NSE inclusion levels were compared using t-
tests; the indicated P values are two-tailed.
Results
SSOs targeting either 3¢ or 5¢ss of the ATMNSE efficiently
repress this exon in a haplotype-dependent manner [18]. To
facilitate identification of optimal intronic SSOs that increase
NSE inclusion in mature transcripts, we first prepared splic-
ing reporter constructs with the entire ATM intron 28
(Fig. 1A). The construct was obtained by PCR using the
HEK293 DNA as a template. The reference sequence (hg19)
of human intron 28 is *3.1 kb long, which is similar to the
average human intron [38]. About 64% of this intron is oc-
cupied by transposed elements, filling completely its middle
part, except for a*350 bp region in the 5¢ half of the intron
and exonic flanks (Fig. 1A). Plasmid DNA sequencing re-
vealed the same organization of transposed elements without
FIG. 2. Identification of intronic SSOs that activate or repress NSE. (A) Location of tested SSOs in intron 28 relative to
transposed elements (for legend, see Fig. 1A). The branch point sequence (GGCTGAT; branch point adenosine is un-
derlined) of NSE is denoted by a vertical arrowhead. (B) Intronic SSOs that alter NSE inclusion in exogenous transcripts.
SSOs are at the bottom. Multiple controls are boxed. SSO sequences are in Table 2. The average NSE inclusion in controls is
denoted by a dotted line, error bars are SDs of two independent transfection experiments. Columns represent mean NSE
inclusion levels, asterisks show significant P values. (C) SSOs targeting single-stranded regions tended to repress en-
dogenous NSE. r, Pearson correlation coefficient. The P value is in brackets. SSOs, splice-switching oligonucleotides.
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any additional transposon copies. It also showed the C and G
alleles at rs4988000 and rs609261, respectively, indicating
that the construct contained the haplotype most permissive
for NSE inclusion in the ATM mRNA [18]. Following
transfections into HEK293 cells, total RNA was extracted
and reverse transcribed before amplification with a combi-
nation of a vector primer PL4 (Table 1) and an exon primer
[18] (Fig. 1A). Examination of spliced products showed that
most transcripts entirely lacked intronic sequences (NSE-),
whereas*36%of themRNA containedNSE (NSE+, Fig. 1B,
lane 1). This fraction was slightly higher than for a hybrid
ATM reporter examined previously [18], consistent with the
presence of auxiliary splicing sequences in newly cloned in-
tronic segments.
To determine the importance of transposed elements for
NSE inclusion, we individually deleted each transposon from
intron 28 (deletions 1–5, Fig. 1A). We also deleted a large
middle part of the intron along with all transposons, leaving
the NSE and its upstream sequences intact, including the
predicted branch site (*75% of the intron, deletion 6).
Transfection of validated mutated constructs, which all had
identical genotypes to the wild-type construct at rs4988000
and rs609261, revealed that the large deletion promoted
NSE-containing transcripts (deletion 6, Fig. 1B). Deletion of
the MER51 element increased NSE inclusion to a lesser ex-
tent. In contrast, deletion of the antisense Alu inhibited NSE,
while deletion of long interspersed repeats (deletions 3 and 5)
or a unique intronic segment (deletion 2) had no effect on
NSE inclusion. The variability of NSE inclusion levels was
higher following transfections of the same plasmids into cells
depleted of U2AF35, with a significant increase of NSE
levels maintained only for deletion 6 (Fig. 1B), consistent
with a major stress component of NSE responses [18].
We next designed a series of SSOs targeting three intronic
regions that have unique sequences in the genome (termed A,
B, and AN) while avoiding a predicted branch site upstream
of NSE (Fig. 2A and Table 2). Each SSO was modified with
2¢-O-methyl at each ribose and phosphorothioate at each end
linkage to ensure their RNase H resistance and sufficient
stability in transient transfections. As a positive control, we
used SSO-NSE3, which was highly efficient in blocking the
NSE 3¢ss [18]. As negative controls, we employed a series of
scrambled SSOs and SSOs targeting other genes, including
INS [24] and BTK [39] (Table 2), which were not expressed
in HEK293 cells, as confirmed by our RNA-Seq data [30].
Each SSO was individually transfected with or without the
wild-type ATM construct. Measurements of spliced products
revealed that SSO-NSE3 yielded the most efficient NSE re-
pression, as expected (Fig. 2B). About a half of tested SSOs
significantly altered NSE inclusion levels compared with con-
trols, with similar numbers of repressor and activator SSOs.
Pearson correlation coefficient between replicate transfections
was highly significant, reaching 0.88 (P<10-8); however, the
overall correlation between exogenous and endogenous NSE
levels was only 0.35 (P<0.01).
Experiments in Fig. 1 showed that NSE inclusion is con-
trolled by distant splicing regulatory sequences within and
outside transposons. Splicing enhancer and silencer motifs in
their natural pre-mRNA context occur preferentially in
single-stranded regions [36], suggesting that they are more
accessible to RNA-binding proteins or other ligands that
control exon selection. Preferential targeting of SSOs to un-
paired regions could thus improve our search strategy. To test
this assumption, we correlated endogenous NSE inclusion
levels after the SSO treatment with their average PU values
(Fig. 2C). These values estimate single-strandedness of their
RNA targets using an equilibriumpartition function,with higher
values signaling a higher probability of single-stranded con-
formation [36]. Interestingly, SSO targets with higher average
PU values tended to induce exon skipping, suggesting that ef-
ficient blocking of unpaired interactions as far as 2 kb from the
exon can impair its inclusion levels in the mRNA.
The experiments described above identified a small set of
intronic SSOs that increased NSE inclusion in exogenous and
endogenous mRNAs and that might serve as gene-specific
repressors since NSE can limit ATM expression through
NMD [18]. ATM repression by NSE-activating SSOs might
be advantageous for cancer treatment by inhibiting the
double-strand break signaling pathway and radiosensitization
[40]. To test if ATM SSOs can be delivered to cells that have
Table 2. Splice-Switching Oligoribonucleotides
SSO 5¢-3¢ Sequencea
A2 aacuuaaagguuauaucuc
A4 uauaaauacgaauaaaucga
A8 cauggguuggcuaugcuag
A9 caacacgacauaaccaaa
A10 aagccaaucagagggagaca
A11 aacauuucuauuuaguuaaaagc
A15 ucguguauuacaacaguuaa
A16 caaccaguuugcauucgu
A17 uuaguauuccuugacuuua
A18 uucuguacacuguuuaguauucc
A19 gaagagggagugaagguu
A20 aaagcuuggugagauuga
A21 uuucuugaaaaguggaaagcuug
A22 uggaaugagggacgguuguuuuuc
A23 gguaugagaacuauagga
A24 aaacaaacagcaggguau
A25 gguaauaagugucacaaa
A26 guaucauacauuagaagg
B1 ucaaaaguaaauuauggucu
B2 gacugguaaauaauaaacauaauuc
B3 aaauguauacuggagaagacu
B4 auauauuagagauacaucagcc
B5 gacaaacauuuaaugaauacucaa
B6 uugacuccuucuuuugacaaacau
B7 uuuaaauccuuccuuacuu
B8 gauuauaaaacaaacgaagc
B10 uguuuuaauauaaguugcuucaa
B11 uguggggugaccacagcuu
B12 ucccuuacuuauauccaa
B13 ccaaguuugguuacuuauc
B14 gaaguuuaucuaauauugacc
AN1 ggucuaucauuaaguuguauga
AN2 uuaaauaagacuucaggucua
AN3 uuagagaaucauuuuaaauaagac
AN4 cuuaauccaauucuucaauuuuag
C1 aggugcucgcgggugg
C2 guugcaaauuucuucaaauc
C3 agcuggggccuggggu
C4 ggaaacuugcccguguucca
aEach SSO was modified with 2¢-O-methyl at each ribose and
phosphorothioate at each end linkage.
SSO, splice-switching oligonucleotide.
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much lower transfection efficiency than HEK293 cells, we
employed a stearylated trimethylated chitosan (TMC-SA).
Chitosan is a natural copolymer of d-glucosamine and N-
acetyl-d-glucosamine known for biocompatibility, biode-
gradability, and low toxicity and immunogenicity [41,42].
When trimethylated, chitosan acquires a permanent positive
charge that improves its solubility at neutral pH [41]. Stear-
ylation was found to be necessary for formation of stable
nanocomplexes with SSOs and their transfection activity [37]
in the HeLa/pLuc705 system, whichmakes use of a luciferase
gene interrupted by a mutated HBB intron [43].
We first tested if TMC-SA can facilitate delivery of SSO-
NSE3 into HEK293 cells. Figure 3A shows reduction of NSE
levels following exposure to the TMC-SA/SSO-NSE3 nano-
complexes compared with a complexed scrambled SSO. This
decline was significant for the TMC-SA/SSO-NSE3 (N/P) ra-
tios 20 and 40. NSE reduction was also apparent when com-
paring NSE inclusion in cells exposed to uncomplexed SSO-
NSE3, consistent with their significant uptake by this highly
transfectable cell line. However, the decline of NSE levels was
smaller for TMC-SA/SSO-NSE3 than for the same oligo
transfected with jetPrime to the same cell line at a lower final
concentration. Finally, significant NSE repression upon expo-
sure to the TMC-SA/SSO-NSE3 nanocomplexeswas observed
also for a lymphoblastoid cell line where uncomplexed SSO-
NSE3 failed to reduce NSE altogether (Fig. 3B).
Discussion
In this work, we have shown for the first time that a
chitosan-based delivery system for intronic SSOs can repress
an NSE (Fig. 3). Our results also demonstrate the first
transposed elements that promote or repress inclusion of an
NSE in mature transcripts (Fig. 1).
Alu sequences have a propensity to exonize through 3¢ss or
5¢ss activation [4,44] or auxiliary splicing motifs [17,45]
upon a single mutation. These events contribute significantly
to humanmorbidity [46]. In addition, they can be exonized by
outlying deletions and cause genetic disease [47], indicating
that they can promote inclusion of remote intronic sequences
in mature transcripts. Although the exact mechanism of such
distant effects is not understood, the secondary structure of
these GC-rich transcripts is likely to play a major role
[46,48]. However, mutation-induced exonization has been
shown for all other classes of transposed elements, including
more ancient, short interspersed elements termedmammalian
interspersed repeats [46]. In the present study, an intronic
transposed element with the highest similarity to MER51A
(MEdium Reiterated frequency repeat, family 51, [49]) re-
pressed NSE, acting as a buffer to counteract the Alu-
mediated NSE activation (Fig. 1A, B). The ATM MER51 is
also relatively GC-rich (*44%), which could facilitate in-
tramolecular interactions with GC-rich Alus during cotran-
scriptional folding. The element contains several inverted
repeats that might form stable hairpins, exposing purine-rich
loops (Fig. 4) that could act as splicing regulatory motifs.
These stem-loops should be examined in future studies to
identify distant interactions underlying the MER-mediated
exonization. About 250,000 copies of recognizable MER
sequences were estimated to exist in the human genome
[38,50] andmany were found inmature transcripts of protein-
coding genes, contributing to the diversity of protein inter-
actions [51]. A mutation-induced MER exonization was also
shown to cause Gitelman syndrome [52]. The 3¢ part of
MER51 is similar to long terminal repeats of retroviruses
(Fig. 4) [49], which account for *15% of transposon-
mediated exonization events leading to human genetic disease
[46]. The origin of most MERs was placed after the decline of
mammalian interspersed repeats before the spread of Alus,
coinciding with the expansion of mammals and suggesting
that MERs may offer insights into early mammalian radiation
[49]. Taken together, our results suggest that the interplay of
transposed elements in long introns could influence inclusion
levels of many NSEs, fine-tuning gene expression.
We have also identified candidate sequence-specific ATM
inhibitors that act by promoting a regulated NSE important
for ATM expression (Fig. 2). ATM inhibitors sensitize cancer
cells to cytotoxic therapy that induces double-strand breaks,
including local radiotherapy, an integral part of treatment
regimens of many cancer types [53]. Although chemical
ATM inhibitors showed great promise, their undesired
pharmacokinetic profiles, high toxicity, or poor efficacy has
hampered their progression into the clinic [53]. In contrast,
SSOs target unique sequences in the human genome, can be
delivered using natural biodegradable compounds (Figs. 1–
3), and their mechanism of action is better defined. In
FIG. 3. TMC-SA-assisted delivery of SSO-NSE3 to human cell lines leads to NSE repression. (A) NSE inclusion in
HEK293 cells is inhibited upon exposure of SSO-NSE3/TMC-SA nanocomplexes. Sc, a scrambled control with the
same modification. M, size marker. Error bars denote SDs of two transfection experiments. P values are shown at the top
for the indicated comparisons. (B) NSE repression in VAVY cells exposed to the SSO-NSE3/TMC-SA nanocomplexes.
TMC-SA, stearylated trimethylated chitosan.
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addition, the availability of NSE-activating and -repressing
SSOs may offer an opportunity to titrate gene expression
more accurately than less specific chemical inhibitors, as-
suming their efficient delivery to newly identified intron 28
targets. Although NSE is included in natural transcripts at
low levels, it can be dramatically upregulated in response to
various stimuli [18,54], requiring further studies into NSE
regulation. Recently, a gene-specific antisense inhibition of
NMD employed SSOs targeting exon junction complex de-
position sites, thus permitting NMD repression without re-
lying on skipping of a PTC-containing exon [26]. The two
approaches, the former relying on intronic sequence and the
latter on exonic targets, might complement each other in the
future to expand the repertoire of antisense strategies that
inhibit NMD.
The average length of SSOs employed in our screening
was close to the minimum for unique targets (Table 2).
Shorter SSOs may induce more off-target effects than longer
SSOs, which could contribute to the observed low correlation
between NSE inclusion levels in endogenous and exogenous
transcripts. Apart from the possible suboptimal target speci-
ficity, intron 28 splicing and NSE inclusion can be influenced
by adjacent introns that were absent in exogenous transcripts.
In addition, intron 28 splicing may not be strictly cotran-
scriptional [18]. Furthermore, distinct promoters of exo- and
endogenous transcripts could be associated with dissimilar
RNA folding or its kinetics, further contributing to the low
correlation. Nevertheless, our study clearly demonstrates a
wealth of candidate intronic target sites for functional SSOs,
in agreement with a high information content of human in-
tronic auxiliary splicing sequences. This content is higher
than in lower organisms, which have smaller introns with a
lower regulatory potential for alternative splicing [22].
Although SSO-NSE3 and other SSOs can repress endoge-
nous NSE-containing mRNAs (Fig. 2B, C) [18] and NMD
transcripts with the relative abundance as low as *1% can
contribute to the mRNA consumption [55], it remains to be
tested if their reduction can lead to a sustained increase of
ATM protein levels in normal cells. Unlike cells depleted of
U2AF subunits where NSE inclusion is high (Fig. 1) andATM
signal on immunoblots was increased upon a single SSO
transfection [18], the low endogenous NSE levels in normal
cells would necessitate a prolonged and repeated SSO expo-
sure and more sensitive assays, ideally coupled with func-
tional analysis of ATM signaling targets. Newly identified
SSOs might also alleviate phenotypic consequences of leaky
ataxia-telangiectasia (A-T) alleles in a mutation-independent
manner, especially in homozygous A-T patients carrying the
C allele at rs609261, which facilitates 3¢ss recognition of the
NSE [18]. Since chitosan-based nanoparticles have been
shown to penetrate the blood–brain barrier and accumulate in
cerebellum [56], SSO-NSE3 and other NSE repressors might
have a future therapeutic potential in slowing down the pro-
gression of cerebellar symptoms of a subset of A-T patients.
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